Aide Nicolas, Poulain Laurent, Elie Nicolas, Briand Mélanie, Giffard Florence, Blanc-Fournier Cécile, Joly Florence, Lasnon Charline
Nuclear Medicine Department, University Hospital, Caen, France.
UNICAEN, INSERM 1086 ANTICIPE, Normandy University, Caen, France.
EJNMMI Res. 2021 Feb 9;11(1):11. doi: 10.1186/s13550-021-00756-z.
Until now, results evaluating the expression of PSMA in ovarian cancer were sparse and contradictory. The aim was to reinvestigate the feasibility of a PSMA targeted theranostic approach in epithelial ovarian cancers with data from the tumour bank of a referring cancer centre.
The OvaRessources Biological Resources Center database was screened from January 2004 to December 2017 to seek patients referred for the initial management of a serous epithelial ovarian cancer and for whom peritoneal histological samples were available in the tumour bank. Immunodetection of PSMA was performed to assess its cellular and neovascular expression. Slides were controlled by a certified pathologist, recorded as tiled tiff images and processed to compute the proportion of DAB stained surface.
Of the 51 patients identified by the database screening, 32 patients were included resulting in 57 samples (32 pre-chemotherapy and 25 post-chemotherapy histological samples). Nine patients were chemo-sensitive, 10 were partially chemo-sensitive and 13 were chemo-resistant/refractory. In the entire dataset, the expression of PSMA was quasi-inexistent: %DAB = 0.04 (± 0.12) %. There was no significant difference in the %DAB of sensitive, partially sensitive and resistant/refractory patients. There was also no significant difference in %DAB in tumours before and after chemotherapy in the 25 patients for whom both samples were available.
The present work demonstrates that PSMA expression is negligible and a fortiori non-sufficient to ensure its usefulness as a prognosticator or a target for a theranostic strategy in ovarian cancers.
到目前为止，评估卵巢癌中前列腺特异性膜抗原（PSMA）表达的研究结果稀少且相互矛盾。本研究旨在利用一家转诊癌症中心肿瘤库的数据，重新探讨PSMA靶向诊疗方法在上皮性卵巢癌中的可行性。
对2004年1月至2017年12月期间的OvaRessources生物资源中心数据库进行筛选，寻找因浆液性上皮性卵巢癌初次治疗而转诊且肿瘤库中有腹膜组织学样本的患者。通过免疫检测PSMA来评估其细胞和新生血管表达。玻片由一名认证病理学家进行对照，记录为平铺式tiff图像，并进行处理以计算DAB染色表面的比例。
通过数据库筛选确定的51例患者中，32例患者被纳入研究，共得到57个样本（32个化疗前和25个化疗后组织学样本）。9例患者化疗敏感，10例患者部分化疗敏感，13例患者化疗耐药/难治。在整个数据集中，PSMA的表达几乎不存在：DAB百分比=0.04（±0.12）%。敏感、部分敏感和耐药/难治患者的DAB百分比无显著差异。在有两个样本的25例患者中，化疗前后肿瘤的DAB百分比也无显著差异。
本研究表明，PSMA表达可忽略不计，更不足以确保其作为卵巢癌预后指标或诊疗策略靶点的有效性。
